Related Experiment Videos
No difference between two doses of diclofenac in prophylaxis of heterotopic ossifications after total hip
Stefan Sell1, Oliver Phillips, Martin Handel
1Department of Orthopedics, Sana Arthritis Hospital, Bad Wildbad, Germany.
Background:
In a monocentric, randomized, placebo-controlled double-blind study, we investigated the efficacy of two doses of diclofenac-cholestyramine for the prevention of heterotopic ossification (HO).
Patients:
The study comprised 245 patients undergoing total hip arthroplasty (THA).
Results:
With 150 mg cholestyramine-bound diclofenac (2 x 1 capsule Voltaren resinate) daily during a postoperative period of 14 days, 19% of patients showed slight HO (Brooker grade 1), and no patient had more severe ossifications (grades 2-4). In the group receiving 75 mg daily (1 x 1 capsule), 17% of patients showed grade 1 HO and 4% grade 2 HO. No patient had grades 3-4 HO. No differences in clinical results were seen between the two groups 6 months after THA.
Interpretation:
Since the rate of adverse gastrointestinal events was lower (23% versus 38%, p = 0.02) in the group receiving the lower dose, we recommend it.
